The landscape for treating transthyretin-mediated (ATTR) amyloidosis—a progressive, often fatal condition caused by the accumulation of misfolded proteins in the heart and nerves—has hit a significant, albeit complex, roadblock. For years, the pharmaceutical industry has been locked in a race to develop “silencing” medications, which work by preventing the liver from producing the mutated proteins that lead to debilitating amyloid deposits.
However, new data presented at the latest European Society of Cardiology (ESC) congress and simultaneously published in the New England Journal of Medicine (NEJM) has thrown a spotlight on the limitations of this approach, particularly when used in combination with standard “stabilizer” therapies. The failure of a late-stage trial for eplontersen (Waiuna), a joint venture between AstraZeneca and Ionis Pharmaceuticals, has not only dimmed the prospects for their specific drug in the cardiomyopathy space but has also cast a shadow over the market dominance of Alnylam Pharmaceuticals’ Amvuttra.
The Core Conflict: Silencers vs. Stabilizers
To understand the gravity of these findings, one must look at the mechanism of disease. ATTR cardiomyopathy occurs when the transthyretin protein becomes unstable, misfolds, and creates toxic amyloid fibrils that infiltrate heart tissue, leading to heart failure.
For years, the standard of care has been dominated by “stabilizers”—drugs like Pfizer’s Vyndamax and BridgeBio’s Attruby—which bind to the protein to keep it in its stable, folded state. More recently, “silencers” like Alnylam’s Amvuttra have been introduced, which use RNA interference to shut down the production of the protein at the source. The prevailing theory among researchers was that combining a stabilizer with a silencer would create a "double-hit" effect, providing additive clinical benefits.
While Alnylam’s HELIOS-B study previously suggested this combination was effective, the recent failure of the CARDIO-TTRansform study has forced analysts and clinicians to reconsider the biological viability of this cocktail approach.
Chronology of a Clinical Pivot
The evolution of this treatment space can be traced through several critical milestones:
- 2022-2023: Alnylam Pharmaceuticals reports positive data from its HELIOS-B trial. The study indicates that adding Amvuttra to standard care provides a survival benefit, leading to widespread optimism and a significant boost in Alnylam’s market valuation.
- July 2024: AstraZeneca and Ionis announce the top-line results of the CARDIO-TTRansform trial. The trial, designed to test eplontersen in a broader population of TTR cardiomyopathy patients, fails to reach its primary endpoint of reducing cardiovascular events or mortality.
- August 2024: The full data set is presented at the ESC Congress and published in the NEJM, revealing that the drug failed to show a statistically significant benefit over a placebo in patients already taking standard stabilizers.
- September 2024: Market analysts begin adjusting their long-term forecasts for Alnylam, AstraZenaca, and Ionis as the medical community questions whether the "silencing" mechanism has reached its ceiling in patients already stabilized by older, traditional medications.
Supporting Data: The CARDIO-TTRansform Failure
The CARDIO-TTRansform trial was a massive undertaking, enrolling over 1,400 volunteers across a global network of clinical sites. The methodology was robust: participants were randomized to receive either eplontersen or a placebo on top of their existing regimen.
The primary endpoint—the reduction of cardiovascular events (such as hospitalizations for heart failure) and all-cause mortality—was missed entirely after 140 weeks of monitoring. The data showed that 29% of patients in the treatment group suffered such events, compared to 32% in the placebo group. While these numbers might seem close, they did not reach the threshold of statistical significance required for regulatory approval in this indication.
Crucially, the demographic profile of the study participants differed significantly from earlier trials. In Alnylam’s HELIOS-B study, only 53% of participants were already on stabilizer medication. In the CARDIO-TTRansform study, that number jumped to 81%. This high baseline of stabilizer usage suggests that by the time a patient is already protected by a stabilizer, the incremental benefit of adding a silencer is potentially negligible.
Official Responses and Expert Analysis
The reaction from the investment community and clinical experts has been one of cautious skepticism regarding the "add-on" model.
"The negative outcome raises the possibility that the incremental benefit of combining a silencer with a stabilizer is smaller than previously assumed," noted Jefferies analyst Michael Leuchten. This sentiment is echoed by many on Wall Street who fear that the "low-hanging fruit" of monotherapy has been picked, and the current strategy of adding more drugs to the patient regimen may not be yielding the expected outcomes.
From the research side, the authors of the NEJM paper pointed to the changing landscape of heart failure management. During the long duration of the trial, standard-of-care treatments evolved, and the use of stabilizers became near-universal. Furthermore, the trial’s broad inclusion criteria meant that many patients were included who were already at a late stage of the disease, where the production of new amyloid proteins may be less critical to the ongoing progression of heart damage than the deposits that have already accumulated.
Implications for the Future of TTR Treatment
1. The Alnylam Question
For Alnylam, the impact is two-fold. While their stock took a hit—falling nearly 30% since the initial July announcement—their commercial reality remains relatively stable. Amvuttra is primarily used as a monotherapy, and most analysts agree that its market position is not immediately threatened by the failure of a competitor’s combination therapy. However, the result casts doubt on the success of their next-generation pipeline product, nucresiran.
2. Strategic Redesign
The failure has prompted a call for a strategic pivot in clinical trial design. Stifel analyst Paul Matteis suggests that for future studies, companies must move away from "combination" designs that assume an additive benefit. Instead, he proposes biasing enrollment toward monotherapy populations or making the impact of a drug as a standalone treatment the primary, rather than secondary, focus.
3. The Rise of "Depleters"
As the limitations of silencers and stabilizers become clear, the industry is shifting its gaze toward a new class of drugs: “depleters.” Unlike silencers (which stop production) or stabilizers (which prevent misfolding), depleters are designed to bind to existing amyloid deposits and physically remove them from the body. With companies like Novo Nordisk and startups like Attralus entering the space, the future of ATTR treatment may lie in "cleaning up" the damage already done, rather than just preventing further accumulation.
Conclusion
The failure of the CARDIO-TTRansform trial is a sobering reminder of the complexities of biological pathways in heart disease. While the dream of a "silver bullet" combination therapy has hit a wall, the data provides a clearer roadmap for future development. The shift toward more targeted populations, earlier intervention, and novel removal mechanisms suggests that while the current generation of silencers has provided a foundation, the next breakthrough in ATTR cardiomyopathy will likely require a more fundamental change in how we address the legacy of amyloid deposits in the heart.
For patients and investors alike, the takeaway is clear: in the world of rare disease, the path to a "standard of care" is rarely a straight line, and the science of today often paves the way for the failures—and ultimate successes—of tomorrow.
About the Author
